Clinical and molecular evaluation of therapy with the use of cyclosporine A in patients with psoriasis vulgaris

ConclusionsTGFb1 may be claimed as the supplementary molecular marker to evaluate the efficacy of CsA therapy. It seems that systemic diseases have an effect on the efficacy of the applied pharmacotherapy and the course of psoriasis.

Source: International Journal of Dermatology - October 22, 2018 Category: Dermatology Authors: Anna Michalska ‐Bańkowska, Dominika Wcisło‐Dziadecka, Beniamin Grabarek, Urszula Mazurek, Ligia Brzezińska‐Wcisło, Piotr Michalski Tags: Report Source Type: research